Key result
Subtype-directed immunosuppression guides tailored clinical management for autoimmune myocarditis.
Why the study?
Autoimmune myocarditis presents a distinct therapeutic challenge because similar clinical syndromes arise from fundamentally different immune mechanisms requiring different treatments, creating a need to synthesize current subtype-specific management evidence.
This narrative review highlights that autoimmune myocarditis requires a subtype-directed therapeutic framework—ranging from corticosteroids to targeted biologics—guided by histopathology, clinical severity, and infectious exclusion.
Answers are grounded in this paper and cite their sources.
May support subtype-directed immunosuppression in autoimmune myocarditis; leaves open the need for prospective trials before practice change.
Autoimmune myocarditis presents a distinct therapeutic challenge: similar clinical syndromes may arise from fundamentally different immune mechanisms and therefore require different treatments. This narrative review synthesizes current evidence for the management of giant cell myocarditis, eosinophilic myocarditis, cardiac sarcoidosis, systemic autoimmune disease-associated myocarditis, immune checkpoint inhibitor-associated myocarditis, and virus-negative immune-mediated lymphocytic myocarditis. We examine how clinical severity, histopathology, infectious exclusion, extracardiac disease, and treatment toxicity shape therapeutic decisions. Although cardiovascular stabilization follows shared principles, immunosuppressive strategies vary substantially across subtypes, ranging from corticosteroids and multidrug immunosuppression to targeted biologic or molecular therapies. We also discuss treatment escalation, monitoring response, and management of fulminant presentations. Across all subtypes, the central challenge is balancing the urgency of suppressing myocardial inflammation against diagnostic uncertainty and treatment-related risk. A subtype-directed approach offers the most clinically meaningful framework for selecting therapy and improving consistency in the management of autoimmune myocarditis.
No takes yet. Share an insight, caveat, or question.
Goh et al. (2026) conducted a review in Autoimmune myocarditis (including giant cell myocarditis, eosinophilic myocarditis, cardiac sarcoidosis, systemic autoimmune disease-associated myocarditis, immune checkpoint inhibitor-associated myocarditis, and virus-negative immune-mediated lymphocytic myocarditis). Subtype-specific immunosuppressive strategies (corticosteroids, multidrug immunosuppression, targeted biologic or molecular therapies) was evaluated. Subtype-directed immunosuppressive strategies ranging from corticosteroids to targeted biologics offer a tailored clinical framework for managing autoimmune myocarditis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: